Sep. 19 at 4:19 PM
$RNAC per Cartesian therapeutics
In regards to future CVR payments, below are highlights from the original License and Development Agreement between Selecta and Sobi for potential payments and royalties that would pull through to CVR holders. Please note that this
$80M of various development and regulatory milestones are ongoing (therefore,
$30M of this
$80M would include the payment for initiating the BLA). Specifics around these milestones, however, are not publicly disclosed until after they are achieved. Similar to the specificities of the
$550M in payments around various sales thresholds of SEL-212, if approved.Up to
$630 million in potential milestone payments
Up to
$80 million in payments upon achievement of various development and regulatory milestones
Up to
$550 million in payments upon achievement of various sales thresholds for annual net sales of SEL-212 ranging from
$100 million to
$1 billion
Royalty payments ranging from low double digits to the high teens
